

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus of the Company dated 2 December 2005 (the "Prospectus") issued by the Company.



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2005)

EXERCISE OF OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus was exercised in full by the Lead Manager (on behalf of the Placing Underwriters) on 21 December 2005 in respect of an aggregate of 10,500,000 Shares, representing 15% of the Offer Shares initially available under the Share Offer. The 10,500,000 Shares will be offered by the Company at HK\$2.15 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.005% and Stock Exchange trading fee of 0.005%), being the Offer Price under the Share Offer.

The Company announces that the Over-allotment Option described in the Prospectus was exercised in full by the Lead Manager (on behalf of the Placing Underwriters) on 21 December 2005 in respect of an aggregate of 10,500,000 Shares (the "Over-allotment Shares"), representing 15% of the Offer Shares initially available under the Share Offer.

The Over-allotment Shares will be offered by the Company at HK\$2.15 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.005% and Stock Exchange trading fee of 0.005%), being the Offer Price under the Share Offer. The Over-allotment Shares will be used solely to cover over-allocations in the Placing.

Listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee. Listing of and dealings in such Over-allotment Shares are expected to commence on the Main Board at 9:30 a.m. on 23 December 2005.

The shareholding structure of the Company immediately before and immediately after the issue of the Over-allotment Shares is as follows:

Shareholders	Immediately before the issue of the Over-allotment Shares		Immediately after the issue of the Over-allotment Shares	
	Number of Shares	Approximate percentage of the Company's issued share capital	Number of Shares	Approximate percentage of the Company's issued share capital
Controlling Shareholders	135,156,000	48.27%	135,156,000	46.53%
Victory Rainbow Investment Limited	52,500,000	18.75%	52,500,000	18.07%
Success Manage International Limited	22,344,000	7.98%	22,344,000	7.69%
Public Shareholders	70,000,000	25.00%	80,500,000	27.71%
	<u>280,000,000</u>	<u>100.00%</u>	<u>290,500,000</u>	<u>100.00%</u>

The net proceeds of approximately HK\$22 million from the issue of the 10,500,000 Over-allotment Shares will be allocated by the Company for the same purposes as set out in the section headed "Future plans" in the Prospectus.

As at the date of this announcement, the Board comprises Wu Qin, Wu Zhihong, Huang Chao, Xie Yunfeng and Sun Xinglai as executive Directors, Liu Zhiyong as non-executive Director and Qu Jiguang, Leung Chong Shun and Chow Kwok Wai as independent non-executive Directors.

By order of the board of
Lijun International Pharmaceutical (Holding) Co., Ltd.
Wu Qin
Chairman

Hong Kong, 21 December 2005